EMERGE BIOSCIENCE
GenericsEMERGE BIOSCIENCE is a generic drug manufacturer focused on Cardiovascular, Respiratory.
EMERGE BIOSCIENCE's Key Drugs
EMERGE BIOSCIENCE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
EMERGE BIOSCIENCE's Recent FDA Approvals
New NDA/BLA approvals for EMERGE BIOSCIENCE over the last two years — novel drugs only, excluding generics and label supplements.
EMERGE BIOSCIENCE's Therapeutic Areas
EMERGE BIOSCIENCE's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EMERGE BIOSCIENCE's Top Competitors
EMERGE BIOSCIENCE's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EMERGE BIOSCIENCE Pipeline Snapshot
Active clinical trials for EMERGE BIOSCIENCE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-12-14
- Latest
- 2026-02-20
- Applications
- 8